407 related articles for article (PubMed ID: 17030078)
1. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
3. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
4. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
6. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
8. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
[TBL] [Abstract][Full Text] [Related]
10. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration routes of vaccines.
Kashima Y; Ikeda M; Itoh Y; Sakoda Y; Nagata T; Miyake T; Soda K; Ozaki H; Nakayama M; Shibuya H; Okamatsu M; Ishigaki H; Ishida H; Sawai T; Kawaoka Y; Kida H; Ogasawara K
Vaccine; 2009 Dec; 27(52):7402-8. PubMed ID: 19747993
[TBL] [Abstract][Full Text] [Related]
12. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
[TBL] [Abstract][Full Text] [Related]
13. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
Van Reeth K; Braeckmans D; Cox E; Van Borm S; van den Berg T; Goddeeris B; De Vleeschauwer A
Vaccine; 2009 Oct; 27(45):6330-9. PubMed ID: 19840669
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets.
Gustin KM; Maines TR; Belser JA; van Hoeven N; Lu X; Dong L; Isakova-Sivak I; Chen LM; Voeten JT; Heldens JG; van den Bosch H; Cox NJ; Tumpey TM; Klimov AI; Rudenko L; Donis RO; Katz JM
J Infect Dis; 2011 Nov; 204(10):1491-9. PubMed ID: 21957153
[TBL] [Abstract][Full Text] [Related]
15. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
[TBL] [Abstract][Full Text] [Related]
16. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
17. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
18. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
[TBL] [Abstract][Full Text] [Related]
19. Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination.
Hwang SD; Shin JS; Ku KB; Kim HS; Cho SW; Seo SH
Vaccine; 2010 Apr; 28(17):2957-64. PubMed ID: 20188684
[TBL] [Abstract][Full Text] [Related]
20. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
